Medicare’s Draft Policy For Alzheimer’s Drugs And The Question Of Cost
Critics of the US Centers for Medicare and Medicaid Services’ proposed decision to restrict Medicare coverage of Aduhelm and similar Alzheimer’s drugs have described the policy as an effort to ration treatments based on cost concerns. Even some supporters are connecting cost to the decision.
You may also be interested in...
After the commercial and public relations debacle driven by Biogen’s original pricing for the companies’ predecessor drug for Alzheimer’s, Aduhelm, Eisai is feeling the heat to ensure the US price for lecanemab is in line with stakeholder expectations.
Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.
Nearly 5,000 comments from individuals on CMS’ proposal to restrict coverage of Alzheimer’s drugs argue that Aduhelm should never have been approved and should not be covered. The outpouring is surprising in light of expectations there would be a flood of patient comments urging broader coverage.